• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Stocks That Hit 52-Week Lows On Friday

    5/27/22 3:28:49 PM ET
    $ACB
    $AERI
    $AGIO
    $ALBO
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ACB alert in real time by email

     

    During Friday's session, 59 stocks hit new 52-week lows.

    Areas of Significance In Today's 52-Week Lows:

    • Medtronic (NYSE:MDT) is the largest company in terms of market cap to set a new 52-week low this morning.
    • Performance Shipping (NASDAQ:PSHG) was the smallest, in terms of market cap, to set a new 52-week low.
    • Performance Shipping (NASDAQ:PSHG)'s stock came under the most pressure, trading down 63.73% to reach a new 52-week low.
    • Sutro Biopharma (NASDAQ:STRO)'s stock bounced back the most, actually rising 0.0% after reaching its new 52-week low.

    The following stocks achieved new 52-week lows on Friday:

    • Medtronic (NYSE:MDT) stock drifted down 1.89% on Friday morning to hit a new 52-week low of $96.86.
    • Mirati Therapeutics (NASDAQ:MRTX) stock dropped to a yearly low on Friday of $32.96. Shares traded down 33.54%.
    • Canopy Gwth (NASDAQ:CGC) stock drifted down 15.33% on Friday morning to hit a new 52-week low of $4.60.
    • Xencor (NASDAQ:XNCR) stock set a new 52-week low of $21.78 on Friday, moving up 0.78%.
    • Iovance Biotherapeutics (NASDAQ:IOVA) stock dropped to a yearly low on Friday of $6.75. Shares traded down 54.13%.
    • Agios Pharmaceuticals (NASDAQ:AGIO) shares made a new 52-week low of $18.55 on Friday. The stock was up 1.7% for the day.
    • SpringWorks Therapeutics (NASDAQ:SWTX) stock hit a yearly low of $13.60. The stock was down 37.04% for the day.
    • Nuvation Bio (NYSE:NUVB) shares hit a yearly low of $3.40. The stock was up 1.73% on the session.
    • I-MAB (NASDAQ:IMAB) stock drifted down 24.23% on Friday morning to hit a new 52-week low of $8.24.
    • Instil Bio (NASDAQ:TIL) stock achieved a new 52-week low on Friday morning, hitting $4.34 and moving down 34.55%.
    • AnaptysBio (NASDAQ:ANAB) stock hit a new 52-week low of $18.24. The stock was up 0.58% on the session.
    • Stoke Therapeutics (NASDAQ:STOK) stock drifted up 0.26% on Friday morning to hit a new 52-week low of $11.28.
    • Bicycle Therapeutics (NASDAQ:BCYC) shares were up 0.33% for the day, having made a 52-week low of $14.44.
    • North Atlantic Acq (NASDAQ:NAAC) stock hit a yearly low of $8.69. The stock was up 0.34% for the day.
    • Albireo Pharma (NASDAQ:ALBO) shares set a new yearly low of $19.51 this morning. The stock was up 1.55% on the session.
    • Aurora Cannabis (NASDAQ:ACB) stock drifted down 39.01% on Friday morning to hit a new 52-week low of $1.63.
    • Day One Biopharmaceutical (NASDAQ:DAWN) stock drifted down 1.04% on Friday morning to hit a new 52-week low of $5.44.
    • Fanhua (NASDAQ:FANH) stock achieved a new 52-week low on Friday morning, hitting $5.07 and moving down 7.24%.
    • Aerie Pharmaceuticals (NASDAQ:AERI) shares made a new 52-week low of $5.20 on Friday. The stock was down 3.22% for the day.
    • Rayonier Adv Materials (NYSE:RYAM) stock hit a yearly low of $3.74. The stock was down 3.85% for the day.
    • Fathom Digital Mfg (NYSE:FATH) stock hit $4.81 on Friday morning, setting a new 52-week low for a change of up 1.23%.
    • Dyne Therapeutics (NASDAQ:DYN) stock set a new 52-week low of $4.36 on Friday, moving up 3.49%.
    • Ocular Therapeutix (NASDAQ:OCUL) stock set a new 52-week low of $2.92 on Friday, moving up 2.33%.
    • ESSA Pharma (NASDAQ:EPIX) shares fell to $5.11 on Friday, setting a new 52-week low with a shift of down 1.89%.
    • Macrogenics (NASDAQ:MGNX) stock hit a new 52-week low of $3.27. The stock was up 1.17% on the session.
    • Sutro Biopharma (NASDAQ:STRO) shares moved 0.0% (flat) on Friday to hit a new 52-week low of $4.19, drifting 0.0% (flat).
    • Cryptyde (NASDAQ:TYDEV) stock hit $9.85 on Friday morning, setting a new 52-week low for a change of down 7.94%.
    • Scholar Rock Holding (NASDAQ:SRRK) shares hit a yearly low of $4.57. The stock was up 3.79% on the session.
    • Omeros (NASDAQ:OMER) stock hit a yearly low of $2.40. The stock was up 8.26% for the day.
    • Zenvia (NASDAQ:ZENV) stock drifted down 4.87% on Friday morning to hit a new 52-week low of $3.63.
    • Allakos (NASDAQ:ALLK) shares set a new 52-week low of $2.56. The stock traded up 1.16%.
    • Surface Oncology (NASDAQ:SURF) stock drifted up 0.73% on Friday morning to hit a new 52-week low of $1.70.
    • Equillium (NASDAQ:EQ) shares hit a yearly low of $1.82. The stock was up 0.69% on the session.
    • Epizyme (NASDAQ:EPZM) stock dropped to a yearly low on Friday of $0.42. Shares traded up 2.12%.
    • Anebulo Pharmaceuticals (NASDAQ:ANEB) shares were down 1.34% for the day, having made a 52-week low of $2.94.
    • Sientra (NASDAQ:SIEN) stock drifted down 4.29% on Friday morning to hit a new 52-week low of $0.99.
    • MSP Recovery (NASDAQ:MSPR) shares made a new 52-week low of $2.21 on Friday. The stock was down 12.26% for the day.
    • Key Tronic (NASDAQ:KTCC) shares set a new yearly low of $4.97 this morning. The stock was up 0.49% on the session.
    • Biotricity (NASDAQ:BTCY) stock hit $0.95 on Friday morning, setting a new 52-week low for a change of up 2.62%.
    • Ocean Power Technologies (AMEX:OPTT) shares made a new 52-week low of $0.86 on Friday. The stock was down 2.23% for the day.
    • Brenmiller Energy (NASDAQ:BNRG) stock achieved a new 52-week low on Friday morning, hitting $3.42 and moving down 7.57%.
    • Comera Life Sciences (NASDAQ:CMRA) stock set a new 52-week low of $2.50 on Friday, moving down 17.48%.
    • OKYO Pharma (NASDAQ:OKYO) stock hit $1.92 on Friday morning, setting a new 52-week low for a change of down 5.28%.
    • PhaseBio Pharmaceuticals (NASDAQ:PHAS) stock drifted up 2.95% on Friday morning to hit a new 52-week low of $0.74.
    • Missfresh (NASDAQ:MF) stock dropped to a yearly low on Friday of $0.15. Shares traded down 4.79%.
    • Kala Pharmaceuticals (NASDAQ:KALA) shares made a new 52-week low of $0.34 on Friday. The stock was up 0.81% for the day.
    • Ayala Pharmaceuticals (NASDAQ:AYLA) shares reached a new 52-week low of $1.48 on Friday morning, moving down 11.16%.
    • Gravitas Education (NYSE:GEHI) stock hit a yearly low of $0.62. The stock was down 9.75% for the day.
    • Shineco (NASDAQ:SISI) shares set a new 52-week low of $1.60. The stock traded down 1.23%.
    • ComSovereign Holding (NASDAQ:COMS) shares hit a yearly low of $0.16. The stock was down 3.05% on the session.
    • Windtree Therapeutics (NASDAQ:WINT) stock broke to a new 52-week low of $0.42 on Friday. Shares of the company traded up 1.1%.
    • Performance Shipping (NASDAQ:PSHG) stock hit $0.64 on Friday morning, setting a new 52-week low for a change of down 63.73%.

    Be sure to monitor Benzinga for the news traders need! And for even more up-to-date info on 52-week lows and highs, check out Benzinga Pro. This cutting-edge market research platform alerts traders of which stocks are trading near their 52-week highs and lows each morning - and delivers lots of other actionable data. Learn more here.

    Get the next $ACB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACB
    $AERI
    $AGIO
    $ALBO

    CompanyDatePrice TargetRatingAnalyst
    Stoke Therapeutics Inc.
    $STOK
    2/5/2026$60.00Buy
    Guggenheim
    Medtronic plc.
    $MDT
    2/3/2026$117.00Buy
    Citigroup
    Medtronic plc.
    $MDT
    1/30/2026$114.00Overweight
    Wells Fargo
    Aurora Cannabis Inc.
    $ACB
    1/27/2026Buy
    Canaccord Genuity
    Sutro Biopharma Inc.
    $STRO
    1/20/2026$23.00Mkt Perform → Mkt Outperform
    Citizens JMP
    Day One Biopharmaceuticals Inc.
    $DAWN
    1/13/2026$34.00Buy
    TD Cowen
    Scholar Rock Holding Corporation
    $SRRK
    1/9/2026$55.00Buy
    Citigroup
    Instil Bio Inc.
    $TIL
    1/7/2026Buy → Neutral
    H.C. Wainwright
    More analyst ratings

    $ACB
    $AERI
    $AGIO
    $ALBO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Invus Global Management, Llc exercised 1,575,008 in-the-money shares at a strike of $7.35 (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    2/6/26 5:35:54 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Operating Officer Notman Donald sold $101,398 worth of shares (11,490 units at $8.82), decreasing direct ownership by 3% to 377,802 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    2/4/26 8:23:42 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Thompson Travis Alvin

    4 - BICYCLE THERAPEUTICS PLC (0001761612) (Issuer)

    2/4/26 7:01:39 PM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACB
    $AERI
    $AGIO
    $ALBO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for TAZVERIK issued to EPIZYME INC

    Submission status for EPIZYME INC's drug TAZVERIK (SUPPL-5) with active ingredient TAZEMETOSTAT HYDROBROMIDE has changed to 'Approval' on 08/13/2024. Application Category: NDA, Application Number: 211723, Application Classification: Labeling

    8/14/24 4:43:30 AM ET
    $EPZM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    April 30, 2024 - FDA Roundup: April 30, 2024

    For Immediate Release: April 30, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA published the FDA Voices: “A Milestone in Facilitating the Development of Safe and Effective Biosimilars,” by Sarah Yim, Director of the Office of New Drugs’ Office of Therapeutic Biologics and Biosimilars, Hilary Marston, M.D., M.P.H., and Patriz

    4/30/24 3:20:20 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    April 26, 2024 - FDA Roundup: April 26, 2024

    For Immediate Release: April 26, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA published the FDA Voices: “A Milestone in Facilitating the Development of Safe and Effective Biosimilars,” by Sarah Yim, Director of the Office of New Drugs’ Office of Therapeutic Biologics and Biosimilars, Hilary Marston, M.D., M.P.H., and Patriz

    4/26/24 3:10:22 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACB
    $AERI
    $AGIO
    $ALBO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Akkaraju Srinivas bought $1,181,634 worth of shares (29,599 units at $39.92) and exercised 1,064,804 in-the-money shares at a strike of $7.35 (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    12/16/25 9:07:57 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Stratmann Philipp bought $2,558 worth of shares (7,750 units at $0.33), increasing direct ownership by 2% to 518,440 units (SEC Form 4)

    4 - Ocean Power Technologies, Inc. (0001378140) (Issuer)

    12/16/25 4:05:27 PM ET
    $OPTT
    Electric Utilities: Central
    Utilities

    CFO Powers Robert Patrick bought $5,000 worth of shares (14,723 units at $0.34), increasing direct ownership by 6% to 268,132 units (SEC Form 4)

    4 - Ocean Power Technologies, Inc. (0001378140) (Issuer)

    12/15/25 4:05:12 PM ET
    $OPTT
    Electric Utilities: Central
    Utilities

    $ACB
    $AERI
    $AGIO
    $ALBO
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Equillium Inc.

    SCHEDULE 13G/A - Equillium, Inc. (0001746466) (Subject)

    2/6/26 4:32:05 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Ocean Power Technologies Inc.

    S-8 - Ocean Power Technologies, Inc. (0001378140) (Filer)

    2/6/26 4:18:33 PM ET
    $OPTT
    Electric Utilities: Central
    Utilities

    SEC Form S-3 filed by Canopy Growth Corporation

    S-3 - Canopy Growth Corp (0001737927) (Filer)

    2/6/26 4:15:52 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACB
    $AERI
    $AGIO
    $ALBO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $ACB
    $AERI
    $AGIO
    $ALBO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Guggenheim initiated coverage on Stoke Therapeutics with a new price target

    Guggenheim initiated coverage of Stoke Therapeutics with a rating of Buy and set a new price target of $60.00

    2/5/26 6:58:02 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup resumed coverage on Medtronic with a new price target

    Citigroup resumed coverage of Medtronic with a rating of Buy and set a new price target of $117.00

    2/3/26 6:56:06 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Wells Fargo resumed coverage on Medtronic with a new price target

    Wells Fargo resumed coverage of Medtronic with a rating of Overweight and set a new price target of $114.00

    1/30/26 9:32:56 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    BEDFORD, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to five newly hired non-executive employees. The awards were made as an inducement material to each recipient's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity awards were granted effective as of February 2, 2026, and consist of non-statutory stock option awards to purchase up to an aggregate of 13,850 shares of Ocular's common stock and a

    2/6/26 4:01:00 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Anebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SEC

    Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today announced that the Company's board of directors (the "Board") has approved the voluntary delisting of the Company's common stock from The Nasdaq Capital Market ("Nasdaq") and the subsequent voluntary deregistration of its common stock with the U.S. Securities and Exchange Commission ("SEC") in order to terminate and suspend its reporting obligations under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Simultaneously with this announcement, Anebulo notified Na

    2/6/26 9:00:00 AM ET
    $ANEB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma

    SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced data demonstrating a best-in-class profile for commercial Amtagvi® (lifileucel) with unprecedented response rates in a real-world clinical, retrospective study in patients with advanced (unresectable or metastatic) melanoma. Amtagvi is the first one-time T cell therapy for a solid tumor cancer as well as the only FDA-approved treatment for advanced melanoma patients previously treated with anti-PD-1 and ta

    2/5/26 5:15:00 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACB
    $AERI
    $AGIO
    $ALBO
    Financials

    Live finance-specific insights

    View All

    Biotricity to Announce Continued Growth in Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11th

    Company continues to drive Revenue Growth, Margin Strength, Operational Efficiency, and continued positive EBITDA REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11th, at 4:30 PM Eastern Time. The Company announces continued progress in its financial performance, including achieving a positive EBITDA and continued growth. Biotricity's Founder and CEO, Dr. Waqa

    2/5/26 4:15:00 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

    SOL-1 Phase 3 superiority trial results remain masked to date SOL-1 data expected to be presented at the 49th Macula Society Annual Meeting Ocular plans to submit NDA for AXPAXLI™ in wet AMD based on SOL-1 52 Week data, pending positive results and planned FDA interactions Completed randomization of 631 subjects in SOL-R Phase 3 non-inferiority trial in December 2025; timing of topline results accelerated and now anticipated in 1Q 2027 HELIOS-3 Phase 3 trial in diabetic retinopathy underway Cash balance of $737.1 million as of December 31, 2025, with expected runway into 2028 BEDFORD, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocula

    2/5/26 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aurora Cannabis Announces Fiscal 2026 Third Quarter Results

    NASDAQ | TSX: ACB Expands YoY Total Net Revenue1 by 7% to $94.2 million, with Global Medical Cannabis Net Revenue1 Increasing by 12% to a Record $76.2 millionDelivers Adjusted EBITDA1 of $18.5 million and Adjusted Net Income1 of $7.2 millionGenerates Free Cash Flow1 of $15.5 million Maintains Strong Balance Sheet with $154.4 million of Cash2 and Short-Term Investments, and a Debt-Free Cannabis Business2EDMONTON, AB, Feb. 4, 2026 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the third quarter 2026 period ending December 31, 2025.

    2/4/26 7:00:00 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACB
    $AERI
    $AGIO
    $ALBO
    Leadership Updates

    Live Leadership Updates

    View All

    Sparrow Appoints Biopharmaceutical Industry Veteran, Carlo Incerti, M.D. to its Board of Directors

    BOSTON, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Sparrow Pharmaceuticals, a targeted cardiometabolic therapeutics company, today announced the appointment of Carlo Incerti, M.D., to its Board of Directors, effective January 1, 2026. Dr. Incerti is a highly accomplished executive with a strong background in medicine and over 35 years of strategic experience in the biopharmaceutical industry. "Carlo's appointment comes at a pivotal moment for Sparrow as we are looking ahead to pivotal trials of clofutriben for type 2 diabetes and seeking to expand development into other cardiometabolic indications," said Robert Jacks, Sparrow President and Chief Executive Officer. "Carlo is respected globally for

    2/2/26 8:30:00 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer

    Accomplished global commercial leader with deep expertise in retina drug launches Primary architect for the industry-defining launch of EYLEA® while at Regeneron Most recently served as Chief Marketing Officer, Global Ophthalmology at Merck BEDFORD, Mass., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that David W. Robinson has agreed to join the Company as Global Chief Commercial Officer. The appointment of Mr. Robinson, a proven commercial leader with a history of launching category-defining therapies, strategically positions Ocular for success

    1/21/26 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morning Market Pulse: AI, Autonomy, and National Security Drive the Narrative at the Open

    DENVER, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Markets are waking up to a distinctly forward-looking tape, with investors parsing developments that point to shifts in Artificial Intelligence infrastructure, advanced sensing, defense-aligned energy systems, and deep-tech R&D platforms. Envirotech Vehicles (NASDAQ:EVTV): Strategic Pivot Toward AI Infrastructure Envirotech Vehicles is in focus after announcing an amended and restated Letter of Intent to acquire AZIO AI Corporation, a move that could dramatically reshape the company's long-term identity. The proposed all-equity transaction values AZIO AI at an assumed enterprise value of $480 million, using a $3.00 per share reference price for E

    1/6/26 9:52:32 AM ET
    $AEVA
    $EVTV
    $OPTT
    Auto Parts:O.E.M.
    Consumer Discretionary
    Electric Utilities: Central
    Utilities

    $ACB
    $AERI
    $AGIO
    $ALBO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Bicycle Therapeutics plc

    SC 13D/A - BICYCLE THERAPEUTICS PLC (0001761612) (Subject)

    12/17/24 6:46:27 PM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ocean Power Technologies Inc.

    SC 13G/A - Ocean Power Technologies, Inc. (0001378140) (Subject)

    11/27/24 1:43:24 PM ET
    $OPTT
    Electric Utilities: Central
    Utilities

    SEC Form SC 13G filed by MacroGenics Inc.

    SC 13G - MACROGENICS INC (0001125345) (Subject)

    11/20/24 10:44:27 AM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care